CL2020002186A1 - Neurotoxina botulinica biohibrida - Google Patents

Neurotoxina botulinica biohibrida

Info

Publication number
CL2020002186A1
CL2020002186A1 CL2020002186A CL2020002186A CL2020002186A1 CL 2020002186 A1 CL2020002186 A1 CL 2020002186A1 CL 2020002186 A CL2020002186 A CL 2020002186A CL 2020002186 A CL2020002186 A CL 2020002186A CL 2020002186 A1 CL2020002186 A1 CL 2020002186A1
Authority
CL
Chile
Prior art keywords
botulinum neurotoxin
biohybrid
receptor
polypeptides
tab
Prior art date
Application number
CL2020002186A
Other languages
English (en)
Spanish (es)
Inventor
Päl Stenmark
Geoffrey Masuyer
Original Assignee
Toxotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toxotech Ab filed Critical Toxotech Ab
Publication of CL2020002186A1 publication Critical patent/CL2020002186A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893Botulinum neurotoxin (3.4.24.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66Enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24Metalloendopeptidases (3.4.24)
    • C12Y304/24069Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91Injection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/55Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Birds (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2020002186A 2018-02-26 2020-08-25 Neurotoxina botulinica biohibrida CL2020002186A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE1850213A SE542539C2 (en) 2018-02-26 2018-02-26 Chimeric botulinum neurotoxin heavy chain binding domain

Publications (1)

Publication Number Publication Date
CL2020002186A1 true CL2020002186A1 (es) 2020-12-28

Family

ID=65576340

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002186A CL2020002186A1 (es) 2018-02-26 2020-08-25 Neurotoxina botulinica biohibrida

Country Status (16)

Country Link
US (2) US20200407702A1 (enExample)
EP (1) EP3759124A1 (enExample)
JP (2) JP7458999B2 (enExample)
KR (1) KR20200127175A (enExample)
CN (1) CN111819189A (enExample)
AU (2) AU2019223130B2 (enExample)
BR (1) BR112020017323A2 (enExample)
CA (1) CA3088928A1 (enExample)
CL (1) CL2020002186A1 (enExample)
IL (1) IL276930A (enExample)
MX (1) MX2020008834A (enExample)
MY (1) MY202690A (enExample)
PH (1) PH12020551270A1 (enExample)
SE (1) SE542539C2 (enExample)
SG (1) SG11202006730SA (enExample)
WO (1) WO2019162376A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019158745A1 (de) * 2018-02-16 2019-08-22 Bontana Therapies Gmbh Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung
IL272002A (en) 2020-01-13 2021-07-29 The Israel Institute Of Biological Res Iibr Methods for identifying anti clostridial neurotoxin compounds
WO2021150581A2 (en) * 2020-01-21 2021-07-29 Trustees Of Dartmouth College Immunologically optimized botulinum toxin light chain variants
CN111675754A (zh) * 2020-05-19 2020-09-18 四川一埃科技有限公司 一种肉毒毒素蛋白晶体结构及晶体制备方法和解析方法
CN114957482B (zh) * 2021-02-26 2024-09-24 重庆誉颜制药有限公司 一种经修饰的神经毒素的单链多肽及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102219837B (zh) * 2010-05-20 2013-10-30 中国人民解放军军事医学科学院微生物流行病研究所 重组全长a型肉毒毒素突变体疫苗
PT2854840T (pt) * 2012-05-30 2018-03-02 Harvard College Neurotoxina botulínica geneticamente modificada
HK1248737A1 (zh) * 2015-03-26 2018-10-19 哈佛大学校长及研究员协会 工程改造的肉毒杆菌神经毒素
TW201718627A (zh) * 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
GB201607901D0 (en) * 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
ES2904269T3 (es) 2016-05-16 2022-04-04 Harvard College Método para la purificación y la activación de la neurotoxina botulínica
EA201892784A1 (ru) * 2016-06-08 2019-05-31 Пол Стенмарк Сконструированные ботулинические нейротоксины

Also Published As

Publication number Publication date
US20200407702A1 (en) 2020-12-31
CA3088928A1 (en) 2019-08-29
MY202690A (en) 2024-05-15
EP3759124A1 (en) 2021-01-06
CN111819189A (zh) 2020-10-23
WO2019162376A1 (en) 2019-08-29
JP2024069606A (ja) 2024-05-21
PH12020551270A1 (en) 2021-05-31
AU2019223130B2 (en) 2024-07-25
JP2021514674A (ja) 2021-06-17
AU2024227611A1 (en) 2024-11-14
US20250034540A1 (en) 2025-01-30
SE542539C2 (en) 2020-06-02
IL276930A (en) 2020-10-29
BR112020017323A2 (pt) 2020-12-29
KR20200127175A (ko) 2020-11-10
JP7458999B2 (ja) 2024-04-01
AU2019223130A1 (en) 2020-09-10
RU2020131317A (ru) 2022-03-29
SG11202006730SA (en) 2020-08-28
MX2020008834A (es) 2021-01-08
SE1850213A1 (en) 2019-08-27

Similar Documents

Publication Publication Date Title
MX2020008834A (es) Biohibrido de neurotoxina botulinica.
CO2021013339A2 (es) Degradadores de stat y usos de los mismos
CO2021002954A2 (es) Anticuerpos anti-αvβ8 y composiciones y usos de los mismos
CO2018000648A2 (es) Compuestos de piridina sustituidos, intermediarios para su preparación y composiciones que los comprenden
CO2018000211A2 (es) Moléculas de anticuerpo que se unen a cd45
CO2018004743A2 (es) Proteínas de unión al antígeno anti-tigit y métodos para usarlas
MX2017000135A (es) Moduladores del receptor arilo y metodos para elaborar y usar los mismos.
CL2021003563A1 (es) Anticuerpos para la unión a psma
BR112019012796A2 (pt) proteínas de ligação ao antígeno antineuropilina e métodos de uso das mesmas
UY37523A (es) Anticuerpos anti-ox40 y sus usos
MX2016012880A (es) Cadena j modificada.
MX359480B (es) Neurotoxina botulínica diseñada.
MX2022015258A (es) Anticuerpos anti-cxcr5 y composiciones y usos de los mismos.
CL2019001668A1 (es) Composiciones cannabinoides novedosas y métodos para tratar la epilepsia infantil.
BR112013021494A2 (pt) liberação de proteínas usando vetores de vírus adeno-associado (aav)
DK3142750T3 (da) Sammensætninger omfattende aav, som udtrykker dobbelt-antistofkonstrukter og anvendelser deraf
EA201490926A1 (ru) Конструкции на основе белка, родственного липопротеинам низкой плотности, 6 (lrp6), и удлинителя полупериода существования
MX2018006385A (es) Moleculas de anticuerpo contra april y usos de las mismas.
CO2018000410A2 (es) Moléculas de anticuerpo que se unen a cd79
BR112017013661A8 (pt) Conjugado derivado de antraciclina (pnu), conjugado de fármaco-proteína de ligação (bpdc), método para a produção de um conjugado de fármaco-proteína de ligação (bpdc), uso de um conjugado de proteína de ligação-fármaco (bpdc) e composição farmacêutica
UY33750A (es) ?Compuestos insecticidas aromáticos derivados de bisamida, procesos e intermediarios para prepararlos y composiciones que los usan.?
BR112016014731A2 (pt) Anticorpos anti-baff
MX2020003783A (es) Moleculas de anticuerpo de cd138 y sus usos.
CO2023015915A2 (es) Anticuerpos anti-ccr8
CO2020013468A2 (es) Agentes de unión a c3 y métodos para su uso